Quitting cold turkey better for smoking cessation.
FROM THE ANNALS OF INTERNAL MEDICINE
Quitting smoking abruptly rather than gradually leads to higher abstinence rates at both 4 weeks and 6 months, a study showed.
Worldwide guidelines for smoking cessation generally recommend abrupt cessation over a gradual reduction in smoking, based on data from observational studies. However a recent review of 10 randomized trials concluded that quitting "cold turkey" produces only slightly higher quit rates, said Nicola Lindson-Hawley, Ph.D., of the department of primary care health services, University of Oxford (England), and her associates.
They compared the two approaches in a noninferiority trial involving 697 adults treated at 31 primary care practices in England during a 2.5-year period. The study participants smoked at least 15 cigarettes per day. The average age was 49 years, and the study population was evenly divided between men and women. Their mean score on the Fagerstrom Test for Cigarette Dependence was 6, indicating a high degree of dependence.
These participants were randomly assigned to either stop smoking abruptly on a quit date 2 weeks from baseline (355 patients) or gradually, by reducing their cigarette use by half at 1 week from baseline, by half again during the second week, and completely by a quit date 2 weeks from baseline. The latter group was given a choice of three structured reduction programs to follow before the quit date, as well as nicotine patches and a choice of short-acting nicotine replacement products. The abrupt-cessation group received only the nicotine patches just before the quit day. Both groups received identical behavioral counseling, nicotine patches, and nicotine replacement products after the quit date.
The primary outcome measure, abstinence at 4 weeks, was achieved by 49% of the abrupt-cessation group, vs. only 39.2% of the gradual-cessation group (relative risk, 0.80). The secondary outcome measure of abstinence at 6 months also was superior for the abrupt-cessation group (22%) over the gradual-cessation group (15.5%), Dr. Lindson-Hawley and her associates reported (Ann Intern Med. 2016 Mar 15. doi: 10.7326/M14-2805).
Dr. Lindson-Hawley reported having no relevant financial disclosures; two of her associates reported ties to Pfizer, GlaxoSmithKline, and McNeil.
BY MARY ANN MOON
|Printer friendly Cite/link Email Feedback|
|Author:||Moon, Mary Ann|
|Publication:||Family Practice News|
|Date:||Apr 1, 2016|
|Previous Article:||Time to look past acetaminophen.|
|Next Article:||Don't abandon gradual approach yet.|